Welcome to our dedicated page for BXRX news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on BXRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BXRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BXRX's position in the market.
In Q3 2021, Baudax Bio (NASDAQ:BXRX) reported a significant revenue increase of 40% from Q2 2021 and over 300% from Q3 2020, driven by strong demand for its pain management product ANJESO. The company experienced a 66% growth in sales to new accounts. Despite challenges from COVID-19 impacting elective surgeries, September marked the highest sales month since ANJESO's launch. The clinical phase for the neuromuscular blocking agent BX1000 is complete, with results expected soon. Baudax reported a net loss of $17 million for Q3 2021.
Baudax Bio (NASDAQ:BXRX) will report its Q3 2021 financial results on November 4, 2021, at 8:00 a.m. ET. The management team will host a conference call and webcast to discuss these results and operational highlights. Baudax Bio specializes in acute care pharmaceuticals, notably its product ANJESO, an IV COX-2 preferential NSAID for managing moderate to severe pain. The press release also highlights potential risks including commercialization challenges, regulatory compliance, and financial stability.
MALVERN, Pa., Oct. 5, 2021 – Baudax Bio (NASDAQ:BXRX) announced a corporate presentation at the NobleCon Pain Management Investor Forum on October 7, 2021. The presentation will be available for registered attendees starting at 11:00 a.m. Eastern Time and can be accessed on Baudax's investor website. Baudax Bio focuses on innovative products for acute care settings, including ANJESO, a 24-hour intravenous NSAID for managing moderate to severe pain, along with a pipeline of neuromuscular blocking agents and a proprietary reversal agent.
Baudax Bio (NASDAQ:BXRX) announced the approval of stock options and restricted stock units for 22 new employees. A total of 242,688 stock options and 79,385 restricted units were granted on September 30, 2021, as part of their employment compensation. The options have an exercise price of $0.56 per share and vest over four years. This grant complies with Nasdaq’s Rule 5635(c)(4) regarding inducement grants. Baudax Bio specializes in innovative products for acute care settings, notably the intravenous NSAID ANJESO.
MALVERN, Pa., Sept. 16, 2021 – Baudax Bio, a pharmaceutical company focused on acute care innovations, announced that CEO Gerri Henwood will participate in a virtual fireside chat during the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Sept. 22, 2021, at 1:15 p.m. ET. A live webcast will be accessible on Baudax Bio's investor page, with a replay available for 30 days post-event. Baudax Bio's primary product, ANJESO, is the first 24-hour intravenous COX-2 preferential NSAID used for moderate to severe pain management, alongside a pipeline of other novel pharmaceutical assets.
Baudax Bio, a pharmaceutical company focused on acute care products, announced that Gerri Henwood, the President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The corporate presentation will be available for on-demand listening starting September 13 at 7:00 a.m. ET, accessible on the company's website. Baudax Bio's key product, ANJESO, is a 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets.
Baudax Bio (BXRX) reported strong growth in ANJESO® sales for Q2 2021, with total vials sold to end-users matching the entire volume of 2020. Key metrics include a 30% increase in total vials sold and a remarkable 150% rise in sales to new ambulatory surgery centers (ASCs). The company successfully added ANJESO® to over 100 formularies and achieved an 82% success rate at P&T committee meetings. Financially, Baudax reported a net loss of $15.3 million for Q2, compared to $30.4 million in the prior year. The company aims to drive adoption of ANJESO® in acute care settings.
Baudax Bio has adjourned its Special Meeting of Shareholders, set to reconvene on August 11, 2021, to further discuss Proposal 1. This proposal seeks to increase the number of authorized shares from 100 million to 190 million. The adjournment aims to provide shareholders additional time to cast their votes, with the record date for eligible voters remaining as June 2, 2021. Shareholders can vote online or by phone, and previously submitted proxies remain valid for the reconvened meeting.
Baudax Bio, Inc. (NASDAQ:BXRX) will report its second quarter 2021 financial results on August 5, 2021. The management will conduct a conference call at 8:00 a.m. ET to discuss these results and recent operational highlights. Baudax Bio's product ANJESO® is the first intravenous NSAID for managing moderate to severe pain, with a pipeline including novel neuromuscular blocking agents. The company faces risks including the impact of COVID-19 on ANJESO's commercial launch and manufacturing capabilities.
Baudax Bio, Inc. (NASDAQ:BXRX) announced that Institutional Shareholder Services (ISS) recommends shareholders vote "FOR" increasing the authorized shares from 100 million to 190 million. This decision will be discussed at the Special Meeting on July 13, 2021. ISS’s support highlights its significance for Baudax's corporate growth and shareholder base expansion. The recommendation is independent, with no prior business relationship between ISS and Baudax. Shareholders are encouraged to participate in the vote and have access to assistance via Okapi Partners.
